Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
T2 Biosystems logo — Rapid detection of sepsis-causing pathogens

T2 Biosystems

Rapid detection of sepsis-causing pathogens

Founded 2006 United States Lexington, United States 140 employees Post-IPO Equity Total: $316.63M Biotechnology, Health Care

General Information

Company Name T2 Biosystems
Founded Year 2006
Location United States Lexington, United States
Employees 140
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with T2 Biosystems. To contact T2 Biosystems, visit t2biosystems.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does T2 Biosystems compare?

A PDF of T2 Biosystems and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting T2 Biosystems soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About T2 Biosystems

T2 Biosystems is dedicated to the rapid detection of sepsis-causing pathogens. The company, established in 2006 and headquartered in the United States, focuses on developing innovative diagnostic products to improve patient health, particularly targeting sepsis, hemostasis, bacteria, and Lyme disease - all areas of significant unmet medical need. Utilizing its proprietary T2 Magnetic Resonance platform (T2MR®), T2 Biosystems aims to lower mortality rates, improve patient outcomes, and reduce healthcare costs by enabling medical professionals to make targeted treatment decisions earlier. As an emerging leader in the field of in vitro diagnostics, T2 Biosystems has received a $15.00MPost-IPO Equity investment from CRG on 15 February 2024. With two FDA-cleared products targeting sepsis, the company continues to develop a broad set of applications to drive positive change in the medical diagnostic landscape. For individuals passionate about advancing healthcare, T2 Biosystems offers opportunities to contribute to its mission through open positions available at www.t2biosystems.com/careers.

Business keywords: medical diagnostics, in vitro diagnostics, sepsis, hemostasis, bacteria, Lyme disease, pathogen detection, T2MR® technology, nanotechnology, magnetic resonance technology, rapid diagnostics, FDA-cleared products, medical innovation, health technology

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $8.00M -
15 May 2024
Post IPO Equity $15.00M 1
CRG
CRG
15 Feb 2024
Grant $3.70M 1
Biomedical Advanced Research and Development Authority (BARDA)
29 Sep 2022
Grant $69.00M 1
Biomedical Advanced Research and Development Authority (BARDA)
11 Sep 2019
Grant $2.00M 1
CARB-X
CARB-X
08 Mar 2018
Post IPO Debt $50.00M 1
CRG
CRG
01 Dec 2016
Post IPO Equity $40.00M 1
Canon
22 Sep 2016
Post IPO Equity $34.13M -
01 Dec 2015
Series E $40.00M 10
Flybridge Goldman Sachs Polaris Partners
Flybridge, Goldman Sachs +8
28 Mar 2013
Series D $23.00M 10
Flybridge Polaris Partners RA Capital Management
Flybridge, Polaris Partners +8
10 Aug 2011

View All 14 Funding Rounds

T2 Biosystems Alternatives & Competitors

View All Alternatives
T2 Biosystems vs
Day Zero Diagnostics, Inc
Day Zero Diagnostics, Inc United States

The future of infectious disease diagnostics starts at Day Zero.

64 employees
Biotechnology, Health Care
Compare T2 Biosystems vs Day Zero Diagnostics, Inc
T2 Biosystems vs
Qvella Corporation
Qvella Corporation Canada

Microbiology in minutes™

36 employees
Biotechnology, Health Care
Compare T2 Biosystems vs Qvella Corporation
T2 Biosystems vs
OmniVis
OmniVis United States

Rapid food borne pathogen detection technology 🦠 Experience the power of the lab in the palm of yo...

Seed
6 employees
Biotechnology, Food and Beverage
View all alternatives

FAQ About T2 Biosystems

Rapid detection of sepsis-causing pathogens
T2 Biosystems was founded in 2006.
T2 Biosystems is headquartered in Lexington, United States.
T2 Biosystems operates in Biotechnology and Health Care. Its work centres on medical diagnostics, in vitro diagnostics, sepsis and hemostasis.
T2 Biosystems has approximately 140 employees.
T2 Biosystems has completed 14 funding rounds, raising a total of $316.63M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to T2 Biosystems include Day Zero Diagnostics, Inc, Qvella Corporation, OmniVis, Qurin, Motus GI Medical Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
T2 Biosystems and Day Zero Diagnostics, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for T2 Biosystems, https://bouncewatch.com/company/t2-biosystems, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout